Company intelligence / Profile preview

Kupando

Schönefeld, Brandenburg, Germanykupando.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Developing KUP101, the only TLR 4/7 agonist in development, consisting of two small molecules co-encapsulated. Currently in IND-enabling work for treatment of solid tumors and prophylaxis of infectious diseases

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesTLR 4/7 agonists
Industry: Biotech

Drug pipeline

1 asset

KUP101

Partnerships

Strategic partnerships mentioned but specific partners not named

Beyond the preview

Go deeper on Kupando.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kupando.

Explore the full profile